- For use in acute respiratory infections in combination with appropriate antibiotic therapy to reduce clinical signs in cattle. For use in diarrhea in combination with oral rehydration therapy, to reduce clinical signs in calves over one week of age and non-lactating young cattle. As adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy. For the relief of post-operative pain in calves after dehorning.
- For use in non-infectious musculoskeletal disorders to reduce the symptoms of lameness and inflammation. As adjunctive therapy in the treatment of puerperal septicemia and toxaemia (mastitis metritis agalactia syndrome) with appropriate antibiotic therapy.
- For use to relieve inflammation and pain in both acute and chronic musculoskeletal disorders. To relieve colic pain.
- Do not use in horses under 6 weeks of age.
- Do not use in pregnant or lactating mares.
- Do not use in animals suffering from impaired hepatic, cardiac or renal function and haemorrhagic disease, or if there is evidence of ulcerogenic gastrointestinal lesions.
- Do not use in case of hypersensitivity to the active substance or to any of the excipients.
- For the treatment of diarrhea in cattle, do not use in animals less than one week old.
Melosolute 20 mg/ml is a solution for injection.
- A single subcutaneous or intravenous injection of 0.5 mg meloxicam/kg body weight (i.e. 2.5 ml/100 kg body weight), in combination with antibiotic therapy or oral rehydration therapy.
- A single intramuscular injection of 0.4 mg meloxicam/kg body weight (i.e. 2.0 ml/100 kg body weight), in combination with antibiotic therapy as appropriate. If necessary, a second dose of meloxicam can be given after 24 hours.
- A single intravenous injection of 0.6 mg meloxicam/kg body weight (i.e. 3.0 ml/100 kg body weight).
The stopper should not be pierced more than 20 times.
One ml contains:
Meloxicam 20 mg
Ethanol (E1510) 150 mg
Melosolute 20 mg/ml is available in a 100 ml vial.
Subcutaneous and intravenous administration (in cattle) and intramuscular administration (in pigs) is well tolerated; only minor transient swelling at the injection site following subcutaneous administration was seen in less than 10% of cattle treated in the clinical trial.
In horses, a transient swelling at the injection site may occur which resolves without treatment.
In very rare cases, anaphylactic reactions can occur which can be serious (including fatal). These should be treated symptomatically.
The frequency of side effects is defined as follows:
- Very common (more than 1 in 10 animals treated show side effect(s))
- Common (more than 1 but less than 10 out of 100 animals treated)
- Uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- Rare (more than 1 but less than 10 animals in 10,000 animals treated)
- Very rare (less than 1 in 10,000 animals treated, including isolated reports)
If side effects occur, treatment should be discontinued.